Hansoh Pharma’s Ris-Rez Succeeds in Phase 3 Osteosarcoma Trial
SHANGHAI, July 28, 2026 Hansoh Pharmaceutical Group Co., Ltd. announced that risvutatug rezetecan (Ris-Rez/HS-20093), its proprietary B7-H3-directed antibody-drug conjugate...
FDA Priority Review
Advertisement
FibroBiologics Advances CYWC628 Phase 1/2 Wound Trial
HOUSTON, July 31, 2026 FibroBiologics, Inc. has begun dosing patients in its Phase 1/2 clinical trial evaluating CYWC628, a...
Johnson & Johnson Advances RYBREVANT for Head and Neck Cancer
RARITAN, N.J., July 30, 2026 Johnson & Johnson has secured U.S. Food and Drug Administration Priority Review for a...
Pfizer Inc. Wins FDA Priority Review for Prostate Cancer Therapy
NEW YORK, July 22, 2026 Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
Persephoni Backs SelSym to Advance Trauma Bleeding Care
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 Persephoni BioSciences has announced a strategic investment in SelSym Biotech, bringing the...
Advertisements
Genentech Wins FDA Priority Review for Gazyva in pMN
SOUTH SAN FRANCISCO, Calif., July 14, 2026 Genentech, a member of the Roche Group, has received U.S. Food and...
Otsuka Reports Positive Phase 3b Results for Centanafadine
TOKYO, Japan & PRINCETON, N.J., June 26, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc....
Alexion’s Ultomiris Gets FDA Priority Review for IgAN
BOSTON, US | June 15, 2026 Alexion, AstraZeneca Rare Disease announced that the U.S. Food and Drug Administration (FDA)...
Takeda Oveporexton Shows Broad Benefits in Narcolepsy
OSAKA, Japan and CAMBRIDGE, Massachusetts, June 15, 2026 Takeda has unveiled new pivotal Phase 3 data demonstrating that oveporexton...
Johnson & Johnson’s IMAAVY Delivers Breakthrough Results in wAIHA
STOCKHOLM, Sweden, June 11, 2026 Johnson & Johnson has reported positive pivotal Phase 2/3 results for IMAAVY® (nipocalimab-aahu) in...
Advertisement
